MiMedx Group (NASDAQ:MDXG) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of MiMedx Group (NASDAQ:MDXG) from a strong-buy rating to a buy rating in a research note released on Saturday.

MDXG has been the subject of several other research reports. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Wednesday, October 8th. Cantor Fitzgerald lifted their target price on MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, MiMedx Group currently has an average rating of “Moderate Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

NASDAQ MDXG opened at $6.73 on Friday. The stock has a market capitalization of $995.77 million, a PE ratio of 32.05 and a beta of 1.73. The business has a 50 day simple moving average of $6.98 and a two-hundred day simple moving average of $6.77. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. MiMedx Group has a 1-year low of $5.69 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. On average, research analysts predict that MiMedx Group will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. OneDigital Investment Advisors LLC lifted its stake in shares of MiMedx Group by 3.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company’s stock worth $419,000 after acquiring an additional 2,056 shares during the last quarter. Alps Advisors Inc. bought a new stake in shares of MiMedx Group during the 1st quarter worth approximately $340,000. New York State Common Retirement Fund lifted its stake in shares of MiMedx Group by 51.8% during the 1st quarter. New York State Common Retirement Fund now owns 87,781 shares of the company’s stock worth $667,000 after acquiring an additional 29,941 shares during the last quarter. Isthmus Partners LLC lifted its stake in shares of MiMedx Group by 1.1% during the 1st quarter. Isthmus Partners LLC now owns 310,262 shares of the company’s stock worth $2,358,000 after acquiring an additional 3,455 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in shares of MiMedx Group during the 1st quarter worth approximately $128,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.